Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?

MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
Open original source
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.
Open original source